Compare GTE & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GTE | ELDN |
|---|---|---|
| Founded | 2003 | 2004 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.7M | 300.3M |
| IPO Year | 2007 | 2014 |
| Metric | GTE | ELDN |
|---|---|---|
| Price | $8.22 | $3.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 338.3K | ★ 1.1M |
| Earning Date | 05-01-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $374,460,000.00 | N/A |
| Revenue This Year | $1.39 | N/A |
| Revenue Next Year | $2.84 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 41.99 | N/A |
| 52 Week Low | $3.09 | $1.35 |
| 52 Week High | $9.74 | $4.60 |
| Indicator | GTE | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 41.31 | 60.04 |
| Support Level | $7.30 | $2.52 |
| Resistance Level | $9.69 | $4.14 |
| Average True Range (ATR) | 0.48 | 0.22 |
| MACD | -0.14 | -0.02 |
| Stochastic Oscillator | 6.54 | 70.55 |
Gran Tierra Energy Inc is an independent energy company. The company, along with its subsidiaries, is focused on oil and gas exploration and production, with assets in Colombia, Canada, and Ecuador. It produces oil, natural gas, and natural gas liquids. Gran Tierra has assembled a diversified, high-quality asset base that is fully operated in Colombia and Ecuador and partly in Canada. The company operates various blocks in Colombia and Ecuador, spanning three basins. It also has contiguous areas in Alberta, Canada, spanning various gross acres across the Western Canadian Sedimentary Basin. The company's reportable segments are Colombia, Ecuador, Canada, and Other. The majority of its revenue comes from operations in Colombia.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.